Could AVA-291 Change Testosterone Therapy For Women?

Could AVA-291 Change Testosterone Therapy For Women?

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Already a member? Sign In

Timeline

00:00

The video opens with the potential implications of a testosterone-like investigational drug reported in preclinical research to be highly resistant to aromatization, including concern that it could eventually be misused by anabolic steroid users.

02:35

Omar Hajmousa explains the regulatory gap in women’s testosterone therapy, including the absence of an FDA-approved female testosterone formulation in the United States and the evidence supporting testosterone for postmenopausal women with hypoactive sexual desire disorder.

05:05

The discussion examines historical concerns about testosterone aromatization and breast cancer while reviewing observational and preclinical findings that challenge assumptions about estrogen conversion and breast-cancer risk.

06:42

AVA-291 is introduced as deuterated testosterone, with Omar explaining how replacing hydrogen with deuterium may alter metabolism and produce strong resistance to aromatization while maintaining androgen-receptor activity in preclinical studies.

10:25

Dr. O’Connor emphasizes that reduced aromatization has only been demonstrated preclinically and discusses both the dosing advantages of a purpose-built formulation for women and the potential for future misuse by men seeking androgenic effects with less estrogen conversion.

16:10

The presentation concludes that AVA-291’s greatest potential value may be providing women with a standardized, quality-controlled testosterone formulation under regulatory oversight rather than simply creating another androgen with reduced aromatization.

Video Summary

AVA-291 could become a purpose-built testosterone option for women if human trials support its promise. Dr. O’Connor and Omar Hajmousa, PharmD, examine this investigational deuterated testosterone, which has shown strong resistance to aromatization in preclinical research while retaining androgen-receptor activity.

The discussion begins with the lack of an FDA-approved testosterone formulation specifically for women in the United States. Current treatment often relies on off-label male formulations or compounded products, creating challenges with concentration, dosing accuracy, quality control, and the risk of accidentally administering substantially more testosterone than intended.

They also examine observational research involving testosterone therapy and breast cancer, while emphasizing that these findings are not randomized clinical-trial evidence. AVA-291’s reduced aromatization may prove scientifically interesting, but its larger potential value could be providing women with a standardized, regulated testosterone formulation specifically designed for them.

Dr. O’Connor also warns that if AVA-291 becomes available, men using anabolic steroids may attempt to misuse it as a highly androgenic testosterone-like compound with minimal estrogen conversion. Because human efficacy, metabolism, and safety data are not yet available, the discussion remains hypothetical and does not endorse investigational or underground use.

Drug Callouts

AVA-291

AVA-291 is an investigational deuterated testosterone discussed as a possible future treatment specifically formulated for women. Preclinical research suggests strong resistance to aromatization while maintaining androgen-receptor activity, but the speakers repeatedly emphasize that human efficacy, metabolism, and safety data are not yet available.

Testosterone

Testosterone is the reference hormone throughout the presentation and is currently prescribed off-label to women in the United States. The discussion contrasts conventional testosterone with AVA-291 while emphasizing dosing accuracy, aromatization, regulatory oversight, and the limitations of existing male formulations when used in women.

Oxandrolone (Anavar)

Oxandrolone is discussed as a synthetic anabolic-androgenic steroid sometimes used in women despite the lack of an evidence base supporting it for hypoactive sexual desire disorder. The speakers contrast this practice with the need for a regulated testosterone formulation designed specifically for women.

Nandrolone

Nandrolone is mentioned as another anabolic-androgenic steroid used off-label by some hormone clinics in women despite the transcript stating that evidence does not support it for hypoactive sexual desire disorder.

Primobolan

Primobolan is discussed while considering how men who misuse anabolic steroids might eventually use AVA-291. Dr. O’Connor compares the theoretical appeal of low-aromatizing deuterated testosterone with combining conventional testosterone and nonaromatizing anabolic steroids.

Masteron

Masteron is discussed alongside Primobolan as an example of a nonaromatizing androgen that some men combine with testosterone. Dr. O’Connor uses the comparison to explain how AVA-291 could theoretically attract misuse if users seek more androgenic exposure without additional estrogen conversion.

Key Takeaways

AVA-291 is an investigational deuterated testosterone that has shown strong resistance to aromatization in preclinical research but does not yet have established human safety or efficacy data.
The United States currently lacks an FDA-approved testosterone formulation specifically designed for women despite evidence supporting testosterone for postmenopausal hypoactive sexual desire disorder.
Using concentrated male testosterone formulations in women can create significant dosing challenges and increase the risk of accidental overadministration.
Observational findings discussed in the presentation question assumptions about testosterone, estrogen conversion, and breast-cancer risk but do not replace randomized clinical trials.
AVA-291’s potential value may lie more in standardized dosing, quality control, and regulatory oversight for women than in reduced aromatization alone.
Dr. O’Connor warns that a minimally aromatizing testosterone-like drug could attract misuse by men seeking anabolic and androgenic effects without additional estrogen conversion.